Evidence map›Paper›PMID 31975963›Full record

ReviewFocus (American Psychiatric Publishing)2019

Treatment for Substance Use Disorder With Co-Occurring Mental Illness.

Muhammad N Iqbal, Charles J Levin, Frances R Levin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Focus (American Psychiatric Publishing), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Psychotherapies in opioid use disorder: toward a step-care model.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  13. Article
  14. Review
  15. Navigating the Intersection of Technology and Depression Precision Medicine.Advances in experimental medicine and biology · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Muhammad N IqbalDivision on Substance Use Disorders, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York (all authors); Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York (F. Levin).
Charles J LevinDivision on Substance Use Disorders, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York (all authors); Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York (F. Levin).
Frances R LevinDivision on Substance Use Disorders, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, New York (all authors); Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York (F. Levin).

Funding

Translational Clinical Research Fellowship on Substance Use DisordersT32DA007294 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Frances Rudnick Levin, Diana M Martinez · 1993 to 2026
$9.3M
Substance Abuse Treatment Development and Clinical Research MentoringK24DA029647 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LEVIN, FRANCES RUDNICK · 2010 to 2019
$1.8M
NIDA NIH HHS K24 DA029647NIDA NIH HHS T32 DA007294
6 · The paper itself

Abstract

Substance use disorder is a highly prevalent condition, leading to significant morbidity, mortality, and burden on the health care system. Substance use disorders are overrepresented among individuals with a mental illness. The term "dual diagnosis" was introduced by the World Health Organization in the mid-1990s and refers to the co-occurrence of a substance use disorder with mental illness-a more recently used term is "co-occurring disorders." In the past decade, substantial progress has been made toward expanding psychotherapeutic and pharmacotherapeutic treatments for treating co-occurring disorders. Yet management remains a challenge among clinicians and has been a source of confusion and considerable controversy. This review describes the epidemiology and treatment of co-occurring disorders, with a focus on major depressive disorder, anxiety disorders, and attention-deficit hyperactivity disorder. Substance use may make diagnosis of the underlying psychiatric condition difficult, and a period of abstinence may be necessary. Findings from efficacy studies of medications used to treat co-occurring disorders are reviewed, as are results of preliminary studies of newer treatments, such as topiramate, ketamine, noninvasive brain stimulation, and deep brain stimulation. Treatment recommendations that combine medications and psychosocial interventions are summarized.

Indexed as

ADHDAlcohol use disorderAnxiety disordersDepressionDual diagnosis

Identifiers

PMID31975963
PMCPMC6526999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.